Use of gabapentin to reduce chronic neuropathic pain in Fabry disease

J Inherit Metab Dis. 2003;26(4):413-4. doi: 10.1023/a:1025127723729.

Abstract

The effect of the anticonvulsant gabapentin on neuropathic pain was studied in six male patients with Fabry disease, aged 15-45 years. After 4 weeks of treatment, pain, as measured using the Brief Pain Inventory, was decreased compared with baseline. Treatment was generally well tolerated. This study indicates that gabapentin should be considered as a treatment option for the neuropathic pain of Fabry disease.

Publication types

  • Clinical Trial

MeSH terms

  • Acetates / adverse effects
  • Acetates / therapeutic use*
  • Adolescent
  • Adult
  • Amines*
  • Anticonvulsants / adverse effects
  • Anticonvulsants / therapeutic use*
  • Cyclohexanecarboxylic Acids*
  • Fabry Disease / complications*
  • Gabapentin
  • Humans
  • Male
  • Neuralgia / drug therapy*
  • Neuralgia / etiology*
  • Neuralgia / physiopathology
  • Pain Measurement
  • Treatment Outcome
  • gamma-Aminobutyric Acid*

Substances

  • Acetates
  • Amines
  • Anticonvulsants
  • Cyclohexanecarboxylic Acids
  • gamma-Aminobutyric Acid
  • Gabapentin